iShares Neuroscience and Healthcare ETF (IBRN)
23.33
-0.22
(-0.94%)
USD |
NYSEARCA |
Mar 28, 16:00
Key Stats
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.47% | 0.37% | 4.692M | 410.43 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.00% | -- | -- | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Small Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | -- |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| NYSE FactSet Glb NeuBio&MedTech TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Greg Savage | 0.52 yrs |
| Jennifer Hsui | 0.52 yrs |
| Paul Whitehead | 0.52 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
--
-2.719B
Category Low
6.230B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of February 28, 2023
Risk
Performance Versus Category
As of March 28, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 28, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Intra-Cellular Therapies Inc | 4.46% | 56.97 | 2.23% |
| Axonics Inc | 4.28% | 56.04 | 2.10% |
| Biogen Inc | 4.26% | 273.17 | 1.08% |
| PTC Therapeutics Inc | 4.24% | 47.50 | 5.27% |
| Alkermes PLC | 4.23% | 27.67 | 1.39% |
| Integra Lifesciences Holdings Corp | 4.21% | 55.40 | -0.14% |
| Neurocrine Biosciences Inc | 4.10% | 96.91 | 0.52% |
| Karuna Therapeutics Inc | 4.06% | 180.84 | 0.44% |
| Catalyst Pharmaceuticals Inc | 4.02% | 16.79 | 2.57% |
| Xenon Pharmaceuticals Inc | 3.97% | 36.18 | 4.51% |
News
Headline
Wire
Time (ET)
SA Breaking News
02/10 16:27
Basic Info
| Investment Strategy | |
| The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Small Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | -- |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | iShares |
| Prospectus Benchmark Index | |
| NYSE FactSet Glb NeuBio&MedTech TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Greg Savage | 0.52 yrs |
| Jennifer Hsui | 0.52 yrs |
| Paul Whitehead | 0.52 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (3-28-23) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of March 27, 2023
Fund Details
| Key Dates | |
| Inception Date | 8/24/2022 |
| Last Annual Report Date | -- |
| Last Prospectus Date | 12/1/2022 |
| Attributes | |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
SA Breaking News
02/10 16:27